Oxford Biomedica plans £60 million equity raise for global expansion

Oxford Biomedica (LSE:OXB) announced a £60 million institutional share placing to fund the expansion of its US cell and gene therapy manufacturing network, aiming for commercial-scale, end-to-end capabilities. This strategic investment is projected to accelerate revenue growth, with fiscal year 2026 revenues now forecast at £220-240 million and 25-30% year-on-year growth in FY2027-2028, alongside a significant increase in operating EBITDA margin to over 20% by FY2027. The move positions the company for increased market share and stronger profitability within the growing viral vector sector, despite unchanged FY2025 guidance.

Analysis

Oxford Biomedica is undertaking a strategic £60 million capital raise via an institutional share placing to finance a significant expansion of its US-based cell and gene therapy manufacturing capabilities. The proceeds are earmarked for achieving commercial-scale, end-to-end production, which the company projects will be a primary catalyst for accelerated growth. This move is supported by a robust upgrade to its financial outlook, forecasting fiscal year 2026 revenue between £220-240 million, followed by 25-30% year-over-year revenue growth in both 2027 and 2028. Critically, this top-line growth is expected to be accompanied by substantial margin expansion, with operating EBITDA margins projected to exceed 10% in FY2026 and reach at least 20% by FY2027. While the company's FY2025 guidance of £160-170 million in revenue remains unchanged, this capital raise signals a clear inflection point aimed at capturing a larger share of a growing market, evidenced by the 2,210 cell and gene therapies currently in clinical pipelines.

Key Decisions for Investors

• Investors should assess the immediate share dilution from the £60 million placing against the company's aggressive forward guidance, which projects a significant acceleration in both revenue growth and profitability from FY2026 onwards.
• The success of this strategy is contingent on execution, so it is critical to monitor milestones related to the US facility expansion and the company's ability to convert this new capacity into the projected revenue and margin growth.
• Consider the favorable industry dynamics, as the expanding pipeline of cell and gene therapies provides a strong tailwind that validates the strategic rationale for increasing manufacturing capacity.